Addition of darolutamide to ADT, docetaxel prolongs OS in metastatic prostate cancer
SAN FRANCISCO — The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged OS among men with metastatic hormone-sensitive prostate cancer, according to study results presented at ASCO Genitourinary Cancers Symposium. The regimen reduced risk for death by 32.5%.